loading page

PHYTONANOMEDICINE: AN INSIGHTS INTO CANCER TREATMENT
  • Vikas Sharma,
  • Rahul Kaushik,
  • Krishan Kumar
Vikas Sharma
Sharda University

Corresponding Author:[email protected]

Author Profile
Rahul Kaushik
Metro College of Health Sciences and Research
Author Profile
Krishan Kumar
Metro College of Health Sciences and Research
Author Profile

Abstract

Background: Nanomedicine, or Phyto nanomedicine, has emerged as a promising solution to enhance therapeutic efficacy by altering the pharmacokinetics and pharmacodynamics of the phytochemicals. Nanomedicines have been developed for enhancing the therapeutic efficacy of the treatments of various diseases. Cancer is the second leading cause of mortality worldwide. Recent findings: Currently available anticancer therapeutic strategies are not sufficient to improve the survival rate of patients. Even significant promising development over the past few decades have not been observed. Recent studies evidenced that cancer cells develop multidrug resistance (MDR) against chemotherapeutics and this leads to enhanced proliferation, invasion and metastasis. Hence, there is an urgent need for an alternative strategy to treat this silent killer. Recently, phytochemicals have gained immense attention as a promising anticancer agent by targeting multimodal oncogenic pathways, inducing cell cycle arrest and apoptosis in preclinical studies. Conclusion: Being multi pathway target oriented Phytochemicals if clubbed with Nanotechnology can prove to be better tool for combating this deadly disease. Therefore, to address these challenges, phytochemical-based nanomedicines (phytonanomedicine) have been developed that not only improve pharmacokinetics profile of drugs but also provide a less toxic multitargeted treatment regimen. In this review, we summarize the current status of nano phytomedicine as anticancer drugs, focusing on the role of phytomedicine in translational cancer research.
31 Jan 20241st Revision Received
02 Feb 2024Assigned to Editor
02 Feb 2024Submission Checks Completed
16 Feb 2024Reviewer(s) Assigned
03 Mar 2024Review(s) Completed, Editorial Evaluation Pending